Table 2

Characteristics of active SLE patients with renal and non-renal involvement

Renal active (n = 19)

Non-renal active (n = 18)


No. male/female

5/14

2/16

Age (yrs), median (range)

38 (18 to 73)

37 (19.60)

SLEDAI, median (range)

12 (6 to 16) ***

8 (5 to 10)

Anti-dsDNA (E/ml), median (range)

230 (7 to 6,683)

234 (3 to 1,000)

C3 (g/l), median (range)

0.58 (0.21 to 1.12) *

0.91 (0.37 to 1.68)

C4 (g/l), median (range)

0.10 (0.04 to 0.30)

0.13 (0.02 to 0.27)

CRP (g/l), median (range)

5 (1 to 81)

9.5 (3 to 92)

No. with/without treatment

17/2

12/6

Users of Prednisone (%) Dose (mg/day), median (range)

14 (78%) 6.25 (2.5 to 100)

7 (39%) 7.50 (5 to 20)

Users of Azathioprine (%) Dose (mg/day), median (range)

2 (11%) 87.5 (75 to 100)

3 (17%) 125 (100 to 150)

Users of Hydroxychloroquine (%) Dose (mg/day), median (range)

8 (42%) 400 (200 to 400)

8 (44%) 400 (200 to 1,200)


* Difference between renal active patients and non-renal active SLE patients. (*P < 0.05, *** P < 0.0001).

Abdulahad et al. Arthritis Research & Therapy 2011 13:R71   doi:10.1186/ar3332

Open Data